Hyderabad(July, 4) : Aurigene Pharmaceutical Services Ltd, a subsidiary of Dr. Reddy’s Laboratories, has announced its plans to establish a state-of-the-art development and manufacturing facility in Hyderabad, India. The facility will focus on niche areas such as therapeutic proteins, antibodies, and viral vectors. With an investment of USD 40 million, Aurigene aims to create around 200 direct job positions and additional indirect job opportunities within the next three years. The company also intends to collaborate with leading biotech innovators to bring innovative medicines to the market, and explore novel therapies like Cell and Gene therapies. This investment reinforces Hyderabad’s position as a thriving hub for biopharmaceutical research and production, contributing to the growth of the biotherapeutics industry in the region.
Satish Reddy, Chairman, Dr. Reddy’s Laboratories and Akhil Ravi, Chief Executive Officer, Aurigene Pharmaceuticals Services Limited met with Minister for Industries and Commerce KT Rama Rao today to brief him on upcoming facility and growth plans of Aurigene Pharmaceutical Services for Hyderabad. Mr. Jayesh Ranjan, Principal Secretary, Industries & Commerce and Shakthi Nagappan, Chief Executive Officer, Telangana Life Sciences were also present during the meeting.
